Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRTC
stocks logo

PRTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for PureTech Health PLC (PRTC.O) is -5.39, compared to its 5-year average forward P/E of -5.71. For a more detailed relative valuation and DCF analysis to assess PureTech Health PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.71
Current PE
-5.39
Overvalued PE
-2.95
Undervalued PE
-8.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.45
Current EV/EBITDA
-1.51
Overvalued EV/EBITDA
-0.74
Undervalued EV/EBITDA
-6.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
68.99
Current PS
0.00
Overvalued PS
120.06
Undervalued PS
17.92
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PRTC News & Events

Events Timeline

(ET)
2025-10-22
05:24:51
PureTech Health unveils fresh insights from the ELEVATE IPF trial
select
2025-09-11 (ET)
2025-09-11
07:16:10
PureTech Health announces first patient dosed in GlyphAgo study by Seaport Therapeutics
select
2025-08-13 (ET)
2025-08-13
12:18:04
PureTech says Vedanta ulcerative colitis study missed endpoint
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
09-29Newsfilter
PureTech Unveils New Findings from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Reinforcing Its Strong and Lasting Efficacy as a Potential New Standard Treatment for IPF

  • Study Findings: Patients who switched to deupirfenidone from placebo or pirfenidone in the ELEVATE IPF trial showed stabilization of lung function, supporting its potential as a new standard of care for idiopathic pulmonary fibrosis (IPF).

  • Regulatory Progress: PureTech Health is actively engaging with regulators regarding the Phase 3 trial design for deupirfenidone, with updates expected in Q4 2025.

[object Object]
Preview
2.0
09-19Benzinga
CoreWeave, Barrick Mining, FedEx, and Other Major Stocks Rise on Friday

  • U.S. Stock Market Performance: U.S. stocks rose on Friday, with the Nasdaq Composite gaining over 100 points, driven by significant increases in various stocks, including CoreWeave, which saw a 4.8% rise after a Buy rating from Loop Capital.

  • Notable Stock Gains: Several companies experienced substantial stock price increases, such as Quantum Computing Inc. (+22.5%), WhiteFiber, Inc. (+17.6%), and Serve Robotics Inc. (+17%), reflecting positive analyst ratings and market momentum.

[object Object]
Preview
9.0
09-11Newsfilter
Seaport Therapeutics, a PureTech-founded entity, Moves Second Therapeutic Candidate GlyphAgo™ (SPT-320) into Clinical Development with First Participant Dosed in Phase 1 Study Involving Healthy Volunteers

  • Introduction of GlyphAgo: GlyphAgo is an oral prodrug of agomelatine, aimed at treating generalized anxiety disorder (GAD) while overcoming limitations related to liver metabolism and side effects associated with traditional agomelatine use.

  • Phase 1 Study Announcement: Seaport Therapeutics has initiated a Phase 1 proof-of-concept study to evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo, marking the second therapeutic candidate from its pipeline to enter clinical development.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PureTech Health PLC (PRTC) stock price today?

The current price of PRTC is 16.3 USD — it has decreased -1.33 % in the last trading day.

arrow icon

What is PureTech Health PLC (PRTC)'s business?

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

arrow icon

What is the price predicton of PRTC Stock?

Wall Street analysts forecast PRTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRTC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PureTech Health PLC (PRTC)'s revenue for the last quarter?

PureTech Health PLC revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is PureTech Health PLC (PRTC)'s earnings per share (EPS) for the last quarter?

PureTech Health PLC. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for PureTech Health PLC (PRTC)'s fundamentals?

The market is revising No Change the revenue expectations for PRTC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 0.42%.
arrow icon

How many employees does PureTech Health PLC (PRTC). have?

PureTech Health PLC (PRTC) has 56 emplpoyees as of December 05 2025.

arrow icon

What is PureTech Health PLC (PRTC) market cap?

Today PRTC has the market capitalization of 405.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free